About the Company
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on aTYR PHARMA INC
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in ...
aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript
aTyr Pharma, Inc. (NASDAQ: ATYR) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Ashlee Dunston - Senior Director of Investor Relations and Public Affairs Sanjay ...
aTyr Pharma Inc ATYR - Morningstar
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 GlobeNewswireApr 29, 2025, 12:00:00 PM ...
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary ...
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...
Atyr Pharma: Q2 Earnings Snapshot
(ATYR) on Thursday reported a loss of $19.5 million in its second quarter. The San Diego-based company said it had a loss of 22 cents per share.
aTyr Pharma to Present at Upcoming Investor Conferences
--aTyr Pharma, Inc., a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that ...
Is aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading ...
We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where aTyr Pharma, Inc.
aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma fourth quarter and full year 2023 conference call. At this time, all participants are in a listen only mode.
aTyr Pharma to Present New Data on the Mechanism of Action of ...
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference Jan. 31, 2023 8:00 AM ET aTyr Pharma, Inc. (ATYR) ...
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary ...
--aTyr Pharma, Inc., a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that ...
aTyr Pharma Inc ATYR - Morningstar
aTyr Pharma Inc ATYR Stock XNAS Rating as of Jun 13, 2025 Download PDF Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends Ownership ...
Similar Companies
Loading the latest forecasts...